See more : National Capital Bancorp, Inc. (NACB) Income Statement Analysis – Financial Results
Complete financial analysis of MYND Life Sciences Inc. (MYND.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MYND Life Sciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Standard Motor Products, Inc. (SMP) Income Statement Analysis – Financial Results
- ENEX Co.,LTD (011090.KS) Income Statement Analysis – Financial Results
- Chrysalis Investments Limited (CHRY.L) Income Statement Analysis – Financial Results
- Elliott Opportunity II Corp. (EOCW-WT) Income Statement Analysis – Financial Results
- Tricom Fruit Products Limited (TRICOMFRU.BO) Income Statement Analysis – Financial Results
MYND Life Sciences Inc. (MYND.CN)
About MYND Life Sciences Inc.
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company is headquartered in Kelowna, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 332.99K | 59.83K | 86.12K | 0.00 | 0.00 |
| Gross Profit | -332.99K | -59.83K | -86.12K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 282.28K | 1.18M | 1.08M | 0.00 | 0.00 |
| General & Administrative | 660.15K | 1.18M | 2.72M | 6.68K | 2.54K |
| Selling & Marketing | 362.07K | 136.16K | 409.46K | 49.79 | 0.00 |
| SG&A | 1.19M | 1.82M | 3.13M | 56.47K | 2.54K |
| Other Expenses | 0.00 | 0.00 | 86.12K | 0.00 | 0.00 |
| Operating Expenses | 1.47M | 3.00M | 4.29M | 56.47K | 2.54K |
| Cost & Expenses | 1.81M | 3.06M | 4.29M | 56.47K | 2.54K |
| Interest Income | 0.00 | 662.91 | 134.88 | 0.00 | 0.00 |
| Interest Expense | 728.41K | 662.91K | 134.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.57K | 59.83K | 86.12K | 56.47K | 2.54K |
| EBITDA | -1.83M | -2.97M | -4.31M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.81M | -3.06M | -4.29M | -56.47K | -2.54K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 289.92K | -693.80K | -243.93K | 0.00 | 0.00 |
| Income Before Tax | -1.52M | -3.70M | -4.54M | -56.47K | -2.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -129.95K | -168.31K | 0.00 | 0.00 |
| Net Income | -1.52M | -3.57M | -4.37M | -56.47K | -2.54K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.08 | -0.10 | 0.00 | 0.00 |
| EPS Diluted | -0.03 | -0.08 | -0.10 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 47.27M | 46.68M | 44.96M | 28.23M | 1.71M |
| Weighted Avg Shares Out (Dil) | 47.27M | 46.68M | 44.96M | 28.23M | 1.71M |
Source: https://incomestatements.info
Category: Stock Reports